Q-omics provides the consensus-scored MTCO1P31 profile across patient tissues and cancer cell-line models. MTCO1P31 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MTCO1P31 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, MTCO1P31 RNA expression shows 11,411 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BRCA, HNSC, and DLBC as cancer lineages where MTCO1P31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P31 survival associations across molecular data types. MTCO1P31 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P31 RNA expression–survival associations across cancer types. High MTCO1P31 expression shows unfavorable associations in LIHC, DLBC and KICH, but favorable associations in BRCA, READ and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for MTCO1P31 RNA expression.
This table summarizes MTCO1P31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P31 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, LIHC, LUSC and KICH. The HNSC box plot shows higher MTCO1P31 RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p = .007).
This table shows molecular features associated with MTCO1P31 in patient tissues and cancer cell lines. In patient samples, MTCO1P31 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
